|
1
|
Goya T, Asamura H, Yoshimura H, et al:
Prognosis of 6644 resected non-small cell lung cancers in Japan: a
Japanese lung cancer registry study. Lung Cancer. 50:227–234. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee SY, Kim MJ, Jin G, et al: Somatic
mutations in epidermal growth factor receptor signaling pathway
genes in non-small cell lung cancers. J Thorac Oncol. 5:1734–1740.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Casas-Selves M, Kim J, Zhang Z, et al:
Tankyrase and the canonical Wnt pathway protect lung cancer cells
from EGFR inhibition. Cancer Res. 72:4154–4164. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ye YZ, Zhang ZH, Fan XY, et al: Notch3
overexpression associates with poor prognosis in human
non-small-cell lung cancer. Med Oncol. 30:5952013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chan AM, McGovern ES, Catalano G, Fleming
TP and Miki T: Expression cDNA cloning of a novel oncogene with
sequence similarity to regulators of small GTP-binding proteins.
Oncogene. 9:1057–1063. 1994.PubMed/NCBI
|
|
6
|
Takai S, Chan AM, Yamada K and Miki T:
Assignment of the human TIM proto-oncogene to 7q33-->q35. Cancer
Genet Cytogenet. 83:87–89. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zheng Y: Dbl family guanine nucleotide
exchange factors. Trends Biochem Sci. 26:724–732. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hart MJ, Eva A, Evans T, Aaronson SA and
Cerione RA: Catalysis of guanine nucleotide exchange on the CDC42Hs
protein by the dbl oncogene product. Nature. 354:311–314. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Debily MA, Camarca A, Ciullo M, et al:
Expression and molecular characterization of alternative
transcripts of the ARHGEF5/TIM oncogene specific for human breast
cancer. Hum Mol Genet. 13:323–334. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xie X, Chang SW, Tatsumoto T, Chan AM and
Miki T: TIM, a Dbl-related protein, regulates cell shape and
cytoskeletal organization in a Rho-dependent manner. Cell Signal.
17:461–471. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Giaccone G and Zucali PA: Src as a
potential therapeutic target in non-small-cell lung cancer. Ann
Oncol. 19:1219–1223. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kuroiwa M, Oneyama C, Nada S and Okada M:
The guanine nucleotide exchange factor Arhgef5 plays crucial roles
in Src-induced podosome formation. J Cell Sci. 124:1726–1738. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li P, Zhang Z, Wang Q, et al: The ectopic
expression of IFN regulatory factor 4-binding protein is correlated
with the malignant behavior of human breast cancer cells. Int
Immunopharmacol. 9:1002–1009. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Maaser K, Daubler P, Barthel B, et al:
Oesophageal squamous cell neoplasia in head and neck cancer
patients: upregulation of COX-2 during carcinogenesis. Br J Cancer.
88:1217–1222. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sharma SV, Oneyama C, Yamashita Y, et al:
UCS15A, a non-kinase inhibitor of Src signal transduction.
Oncogene. 20:2068–2079. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lazer G and Katzav S: Guanine nucleotide
exchange factors for RhoGTPases: good therapeutic targets for
cancer therapy? Cell Signal. 23:969–979. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hou M, Tan L, Wang X and Zhu YS: Antisense
Tiam1 down-regulates the invasiveness of 95D cells in vitro. Acta
Biochim Biophys Sin. 36:537–540. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hirata D, Yamabuki T, Miki D, et al:
Involvement of epithelial cell transforming sequence-2 oncoantigen
in lung and esophageal cancer progression. Clin Cancer Res.
15:256–266. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fernandez-Zapico ME, Gonzalez-Paz NC,
Weiss E, et al: Ectopic expression of VAV1 reveals an unexpected
role in pancreatic cancer tumorigenesis. Cancer Cell. 7:39–49.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lazer G, Idelchuk Y, Schapira V, Pikarsky
E and Katzav S: The haematopoietic specific signal transducer Vav1
is aberrantly expressed in lung cancer and plays a role in
tumourigenesis. J Pathol. 219:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Brantley-Sieders DM, Zhuang G, Vaught D,
et al: Host deficiency in Vav2/3 guanine nucleotide exchange
factors impairs tumor growth, survival, and angiogenesis in vivo.
Mol Cancer Res. 7:615–623. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Serrano-Olvera A and Gerson R: Age
associated survival rate in non small cell lung cancer. Gac Med
Mex. 145:27–35. 2009.(In Spanish).
|
|
23
|
Salmeron D, Chirlaque MD, Isabel
Izarzugaza M, et al: Lung cancer prognosis in Spain: the role of
histology, age and sex. Respir Med. 106:1301–1308. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu W, Allbritton N and Lawrence DS: SRC
kinase regulation in progressively invasive cancer. PLoS One.
7:e488672012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Budde RJ, Ke S and Levin VA: Activity of
pp60c-src in 60 different cell lines derived from human tumors.
Cancer Biochem Biophys. 14:171–175. 1994.PubMed/NCBI
|
|
26
|
Mazurenko NN, Kogan EA, Zborovskaya IB and
Kisseljov FL: Expression of pp60c-src in human small cell and
non-small cell lung carcinomas. Eur J Cancer. 28:372–377. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Masaki T, Igarashi K, Tokuda M, et al:
pp60c-src activation in lung adenocarcinoma. Eur J Cancer.
39:1447–1455. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Thomas SM and Brugge JS: Cellular
functions regulated by Src family kinases. Annu Rev Cell Dev Biol.
13:513–609. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Laird AD, Li G, Moss KG, et al: Src family
kinase activity is required for signal tranducer and activator of
transcription 3 and focal adhesion kinase phosphorylation and
vascular endothelial growth factor signaling in vivo and for
anchorage-dependent and -independent growth of human tumor cells.
Mol Cancer Ther. 2:461–469. 2003.
|
|
30
|
Song L, Turkson J, Karras JG, Jove R and
Haura EB: Activation of Stat3 by receptor tyrosine kinases and
cytokines regulates survival in human non-small cell carcinoma
cells. Oncogene. 22:4150–4165. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Eliceiri BP, Paul R, Schwartzberg PL, Hood
JD, Leng J and Cheresh DA: Selective requirement for Src kinases
during VEGF-induced angiogenesis and vascular permeability. Mol
Cell. 4:915–924. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sato M, Tanaka T, Maeno T, et al:
Inducible expression of endothelial PAS domain protein-1 by hypoxia
in human lung adenocarcinoma A549 cells. Role of Src family
kinases-dependent pathway. Am J Respir Cell Mol Biol. 26:127–134.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Johnson FM, Bekele BN, Feng L, et al:
Phase II study of dasatinib in patients with advanced
non-small-cell lung cancer. J Clin Oncol. 28:4609–4615. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Haura EB, Tanvetyanon T, Chiappori A, et
al: Phase I/II study of the Src inhibitor dasatinib in combination
with erlotinib in advanced non-small-cell lung cancer. J Clin
Oncol. 28:1387–1394. 2010. View Article : Google Scholar : PubMed/NCBI
|
